- All sections
- C - Chemistrymetallurgy
- C07C - Acyclic or carbocyclic compounds
- C07C 251/32 - Oximes
Patent holdings for IPC class C07C 251/32
Total number of patents in this class: 24
10-year publication summary
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ambrx, Inc. | 170 |
3 |
| University of Southampton | 451 |
2 |
| BASF SE | 21113 |
1 |
| The Regents of the University of California | 20534 |
1 |
| AstraZeneca AB | 2836 |
1 |
| AstraZeneca UK Limited | 558 |
1 |
| Syngenta Crop Protection AG | 6466 |
1 |
| Shin-Etsu Chemical Co., Ltd. | 5948 |
1 |
| Advansix Resins & Chemicals LLC | 303 |
1 |
| Cognis IP Management GmbH | 581 |
1 |
| GE Healthcare Limited | 644 |
1 |
| Guangzhou Magpie Pharmaceutical Co., Ltd | 1 |
1 |
| Kyung Nong Corporation | 16 |
1 |
| Oak Ridge National Laboratory | 3 |
1 |
| Screen Holdings Co., Ltd. | 3100 |
1 |
| Universidad de Leon | 26 |
1 |
| Universidad Publica de Navarra | 47 |
1 |
| The University of Melbourne | 554 |
1 |
| University of Tennessee Research Foundation | 757 |
1 |
| Universidad del Pais Vasco-Euskal Herriko Unibertsitatea | 110 |
1 |
| Other owners | 1 |